-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
trial	O
in	O
the	O
investigation	O
of	O
anxiety	O
and	O
depression	O
in	O
patients	B-P
with	I-P
coronavirus	I-P
disease	I-P
2019	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
.	O

METHODS	O
:	O
Sixty	B-P
-	I-P
five	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
randomly	O
enrolled	O
into	O
this	O
study	O
.	O

Anxiety	B-O
and	O
depression	B-O
among	O
participants	O
were	O
measured	O
through	O
the	O
completion	O
of	O
anonymous	B-O
Chinese	I-O
-	I-O
language	I-O
Zung	I-O
self	I-O
-	I-O
rating	I-O
anxiety	I-O
scale	I-O
and	O
self	B-O
-	I-O
rating	I-O
depression	I-O
scale	I-O
questionnaires	I-O
.	O

Data	O
were	O
analyzed	O
using	O
independent	O
samples	O
t	O
-	O
tests	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
and	O
?2	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Intermediate	B-I
-	I-I
Dose	I-I
vs	O
Standard	B-C
-	I-C
Dose	I-C
Prophylactic	I-C
Anticoagulation	I-C
on	O
Thrombotic	O
Events	O
,	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Treatment	O
,	O
or	O
Mortality	O
Among	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
Admitted	I-P
to	I-P
the	I-P
Intensive	I-P
Care	I-P
Unit	I-P
:	O
The	O
INSPIRATION	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
randomized	O
trial	O
with	O
a	O
2	O
	O
2	O
factorial	O
design	O
performed	O
in	O
10	O
academic	O
centers	O
in	O
Iran	O
comparing	O
intermediate	B-I
-	I-I
dose	I-I
vs	O
standard	B-C
-	I-C
dose	I-C
prophylactic	I-C
anticoagulation	I-C
(	O
first	O
hypothesis	O
)	O
and	O
statin	B-I
therapy	I-I
vs	O
matching	B-C
placebo	I-C
(	O
second	O
hypothesis	O
;	O
not	O
reported	O
in	O
this	O
article	O
)	O
among	O
adult	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
ICU	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
recruited	O
between	O
July	O
29	O
,	O
2020	O
,	O
and	O
November	O
19	O
,	O
2020	O
.	O

The	O
final	O
follow	O
-	O
up	O
date	O
for	O
the	O
30	O
-	O
day	O
primary	O
outcome	O
was	O
December	O
19	O
,	O
2020	O
.	O

Intermediate	B-I
-	I-I
dose	I-I
(	I-I
enoxaparin	I-I
,	O
1	O
mg	O
/	O
kg	O
daily	O
)	O
(	O
n	O
=	O
276	O
)	O
vs	O
standard	B-C
prophylactic	I-C
anticoagulation	I-C
(	I-C
enoxaparin	I-C
,	O
40	O
mg	O
daily	O
)	O
(	O
n	O
=	O
286	O
)	O
,	O
with	O
modification	O
according	O
to	O
body	O
weight	O
and	O
creatinine	O
clearance	O
.	O

The	O
assigned	O
treatments	O
were	O
planned	O
to	O
be	O
continued	O
until	O
completion	O
of	O
30	O
-	O
day	O
follow	O
-	O
up	O
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
a	B-O
composite	I-O
of	I-O
venous	I-O
or	O
arterial	B-O
thrombosis	I-O
,	O
treatment	B-O
with	I-O
extracorporeal	I-O
membrane	I-O
oxygenation	I-O
,	O
or	O
mortality	B-O
within	O
30	O
days	O
,	O
assessed	O
in	O
randomized	O
patients	O
who	O
met	O
the	O
eligibility	O
criteria	O
and	O
received	O
at	O
least	O
1	O
dose	O
of	O
the	O
assigned	O
treatment	O
.	O

Prespecified	O
safety	O
outcomes	O
included	O
major	B-O
bleeding	I-O
according	O
to	O
the	B-O
Bleeding	I-O
Academic	I-O
Research	I-O
Consortium	I-O
(	I-O
type	I-O
3	I-O
or	I-O
5	I-O
definition	I-O
)	I-O
,	O
powered	B-O
for	I-O
noninferiority	I-O
(	O
a	O
noninferiority	O
margin	O
of	O
1	O
.	O
8	O
based	O
on	O
odds	O
ratio	O
)	O
,	O
and	O
severe	B-O
thrombocytopenia	I-O
(	O
platelet	O
count	O
<	O
20	O
103	O
/	O
L	O
)	O
.	O

All	O
outcomes	O
were	O
blindly	O
adjudicated	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
Favipiravir	B-I
in	O
moderate	O
to	O
severe	O
SARS	O
-	O
CoV	O
-	O
2	O
pneumonia	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
multicenter	O
randomized	O
open	O
-	O
labeled	O
clinical	O
trial	O
on	O
moderate	O
to	O
severe	O
cases	O
infections	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

Patients	B-P
with	I-P
typical	I-P
ground	I-P
glass	I-P
appearance	I-P
on	I-P
chest	I-P
computerized	I-P
tomography	I-P
scan	I-P
(	I-P
CT	I-P
scan	I-P
)	I-P
and	I-P
oxygen	I-P
saturation	I-P
(	I-P
SpO2	I-P
)	I-P
of	I-P
less	I-P
than	I-P
93	I-P
%	I-P
were	O
enrolled	O
.	O

They	O
were	O
randomly	O
allocated	O
into	O
Favipiravir	B-I
(	O
1	O
.	O
6	O
gr	O
loading	O
,	O
1	O
.	O
8	O
gr	O
daily	O
)	O
and	O
Lopinavir	B-I
/	O
Ritonavir	B-I
(	O
800	O
/	O
200	O
mg	O
daily	O
)	O
treatment	O
regimens	O
in	O
addition	O
to	O
standard	B-I
care	I-I
.	O

In	B-O
-	I-O
hospital	I-O
mortality	I-O
,	O
ICU	B-O
admission	I-O
,	O
intubation	B-O
,	O
time	B-O
to	I-O
clinical	I-O
recovery	I-O
,	O
changes	O
in	O
daily	B-O
SpO2	I-O
after	O
5	O
min	O
discontinuation	O
of	O
supplemental	O
oxygen	O
,	O
and	O
length	B-O
of	I-O
hospital	I-O
stay	I-O
were	O
quantified	O
and	O
compared	O
in	O
the	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Itraconazole	B-I
for	O
COVID	O
-	O
19	O
:	O
preclinical	O
studies	O
and	O
a	O
proof	O
-	O
of	O
-	O
concept	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Due	O
to	O
the	O
initial	O
absence	O
of	O
preclinical	O
models	O
,	O
the	O
effect	O
of	O
itraconazole	B-I
was	O
explored	O
in	O
a	O
clinical	O
,	O
proof	O
-	O
of	O
-	O
concept	O
,	O
open	O
-	O
label	O
,	O
single	O
-	O
center	O
study	O
,	O
in	O
which	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
standard	B-I
of	I-I
care	I-I
with	O
or	O
without	O
itraconazole	B-I
.	O

Primary	O
outcome	O
was	O
the	B-O
cumulative	I-O
score	I-O
of	I-O
the	I-O
clinical	I-O
status	I-O
until	O
day	O
15	O
based	O
on	O
the	B-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
of	I-O
the	I-O
World	I-O
Health	I-O
Organization	I-O
.	O

In	O
parallel	O
,	O
itraconazole	B-I
was	O
evaluated	O
in	O
a	O
newly	O
established	O
hamster	O
model	O
of	O
acute	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
and	O
transmission	O
,	O
as	O
soon	O
as	O
the	O
model	O
was	O
validated	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
Levamisole	B-I
treatment	I-I
in	O
clinical	O
presentations	O
of	O
non	B-P
-	I-P
hospitalized	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
clinical	O
trial	O
was	O
performed	O
in	O
adult	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
room	I-P
-	I-P
air	I-P
oxygen	I-P
saturation	I-P
>	I-P
94	I-P
%	I-P
)	I-P
from	I-P
late	I-P
April	I-P
2020	I-P
to	I-P
mid	I-P
-	I-P
August	I-P
2020	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	B-I
3	I-I
-	I-I
day	I-I
course	I-I
of	I-I
Levamisole	I-I
or	O
placebo	B-C
in	O
combination	O
with	O
routine	B-I
standard	I-I
of	I-I
care	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Helmet	B-I
Noninvasive	I-I
Ventilation	I-I
vs	O
High	B-I
-	I-I
Flow	I-I
Nasal	I-I
Oxygen	I-I
on	O
Days	O
Free	O
of	O
Respiratory	O
Support	O
in	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
Moderate	I-P
to	I-P
Severe	I-P
Hypoxemic	I-P
Respiratory	I-P
Failure	I-P
:	O
The	O
HENIVOT	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
randomized	O
clinical	O
trial	O
in	O
4	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Italy	O
between	O
October	O
and	O
December	O
2020	O
,	O
end	O
of	O
follow	O
-	O
up	O
February	O
11	O
,	O
2021	O
,	O
including	O
109	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
moderate	I-P
to	I-P
severe	I-P
hypoxemic	I-P
respiratory	I-P
failure	I-P
(	I-P
ratio	I-P
of	I-P
partial	I-P
pressure	I-P
of	I-P
arterial	I-P
oxygen	I-P
to	I-P
fraction	I-P
of	I-P
inspired	I-P
oxygen	I-P
?200	I-P
)	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
continuous	B-I
treatment	I-I
with	I-I
helmet	I-I
noninvasive	I-I
ventilation	I-I
(	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
10	O
-	O
12	O
cm	O
H2O	O
;	O
pressure	O
support	O
,	O
10	O
-	O
12	O
cm	O
H2O	O
)	O
for	O
at	O
least	O
48	O
hours	O
eventually	O
followed	O
by	O
high	B-I
-	I-I
flow	I-I
nasal	I-I
oxygen	I-I
(	O
n	O
=	O
54	O
)	O
or	O
high	B-I
-	I-I
flow	I-I
oxygen	I-I
alone	I-I
(	O
60	O
L	O
/	O
min	O
)	O
(	O
n	O
=	O
55	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
respiratory	I-O
support	I-O
within	O
28	O
days	O
after	O
enrollment	O
.	O

Secondary	O
outcomes	O
included	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
who	I-O
required	I-O
endotracheal	I-O
intubation	I-O
within	O
28	O
days	O
from	O
study	O
enrollment	O
,	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
at	O
day	O
28	O
,	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
at	O
day	O
60	O
,	O
in	B-O
-	I-O
ICU	I-O
mortality	I-O
,	O
in	B-O
-	I-O
hospital	I-O
mortality	I-O
,	O
28	B-O
-	I-O
day	I-O
mortality	I-O
,	O
60	B-O
-	I-O
day	I-O
mortality	I-O
,	O
ICU	B-O
length	I-O
of	I-O
stay	I-O
,	O
and	O
hospital	B-O
length	I-O
of	I-O
stay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
omega	B-I
-	I-I
3	I-I
fatty	I-I
acid	I-I
supplementation	I-I
on	O
clinical	O
and	O
biochemical	O
parameters	O
of	O
critically	B-P
ill	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
,	O
randomized	O
clinical	O
trial	O
study	O
was	O
conducted	O
on	O
128	B-P
critically	I-P
ill	I-P
patients	I-P
infected	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
who	O
were	O
randomly	O
assigned	O
to	O
the	O
intervention	O
(	O
fortified	B-I
formula	I-I
with	I-I
n3	I-I
-	I-I
PUFA	I-I
)	O
(	O
n	O
=	O
42	O
)	O
and	O
control	O
(	O
n	O
=	O
86	O
)	O
groups	O
.	O

Data	O
on	O
1	B-O
month	I-O
survival	I-O
rate	I-O
,	O
blood	B-O
glucose	I-O
,	O
sodium	B-O
(	I-O
Na	I-O
)	I-O
,	O
potassium	B-O
(	I-O
K	I-O
)	I-O
,	O
blood	B-O
urea	I-O
nitrogen	I-O
(	I-O
BUN	I-O
)	I-O
,	O
creatinine	B-O
(	I-O
Cr	I-O
)	I-O
,	O
albumin	B-O
,	O
hematocrit	B-O
(	I-O
HCT	I-O
)	I-O
,	O
calcium	B-O
(	I-O
Ca	I-O
)	I-O
,	O
phosphorus	B-O
(	I-O
P	I-O
)	I-O
,	O
mean	B-O
arterial	I-O
pressure	I-O
(	I-O
MAP	I-O
)	I-O
,	O
O2	B-O
saturation	I-O
(	I-O
O2sat	I-O
)	I-O
,	O
arterial	B-O
pH	I-O
,	O
partial	B-O
pressure	I-O
of	I-O
oxygen	I-O
(	I-O
PO2	I-O
)	I-O
,	O
partial	B-O
pressure	I-O
of	I-O
carbon	I-O
dioxide	I-O
(	I-O
PCO2	I-O
)	I-O
,	O
bicarbonate	B-O
(	I-O
HCO3	I-O
)	I-O
,	O
base	B-O
excess	I-O
(	I-O
Be	I-O
)	I-O
,	O
white	B-O
blood	I-O
cells	I-O
(	I-O
WBCs	I-O
)	I-O
,	O
Glasgow	B-O
Coma	I-O
Scale	I-O
(	I-O
GCS	I-O
)	I-O
,	O
hemoglobin	B-O
(	I-O
Hb	I-O
)	I-O
,	O
platelet	B-O
(	I-O
Plt	I-O
)	I-O
,	O
and	O
the	B-O
partial	I-O
thromboplastin	I-O
time	I-O
(	I-O
PTT	I-O
)	I-O
were	O
collected	O
at	O
baseline	O

and	O
after	O
14	O
days	O
of	O
the	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Observation	O
of	O
therapeutic	O
effect	O
on	O
coronavirus	O
disease	O
2019	O
with	O
insomnia	O
in	O
treatment	O
with	O
baduanjin	B-I
and	O
auricular	B-I
point	I-I
sticking	I-I
therapy	I-I
]	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
90	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
accompanied	I-P
with	I-P
insomnia	I-P
were	O
randomly	O
divided	O
into	O
an	O
observation	O
group	O
(	O
45	O
cases	O
,	O
3	O
cases	O
dropped	O
off	O
)	O
and	O
a	O
control	O
group	O
(	O
45	O
cases	O
)	O
.	O

In	O
the	O
observation	O
group	O
,	O
baduanjin	B-I
,	O
a	B-I
traditional	I-I
Chinese	I-I
fitness	I-I
activity	I-I
,	O
was	O
practiced	O
everyday	O
.	O

Besides	O
,	O
auricular	B-I
point	I-I
sticking	I-I
therapy	I-I
was	O
exerted	O
at	O
ear	O
-	O
shenmen	O
(	O
TF	O
4	O
)	O
,	O
subcortex	O
(	O
AT	O
4	O
)	O
,	O
heart	O
(	O
CO	O
15	O
)	O
,	O
occiput	O
(	O
AT	O
3	O
)	O
,	O
etc	O
.	O

These	O
auricular	O
points	O
were	O
pressed	O
and	O
kneaded	O
three	O
times	O
a	O
day	O
,	O
30	O
s	O
at	O
each	O
point	O
each	O
time	O
,	O
consecutively	O
for	O
12	O
days	O
.	O

In	O
the	O
control	O
group	O
,	O
estazolam	B-C
tablets	O
were	O
prescribed	O
for	O
oral	O
administration	O
,	O
1	O
mg	O
,	O
once	O
daily	O
,	O
consecutively	O
for	O
12	O
days	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	B-O
score	I-O
of	I-O
Pittsburgh	I-O
sleep	I-O
quality	I-O
index	I-O
(	I-O
PSQI	I-O
)	I-O
,	O
the	B-O
score	I-O
of	I-O
self	I-O
-	I-O
rating	I-O
anxiety	I-O
scale	I-O
(	I-O
SAS	I-O
)	I-O
,	O
the	B-O
score	I-O
of	I-O
self	I-O
-	I-O
rating	I-O
depression	I-O
scale	I-O
(	I-O
SDS	I-O
)	I-O
and	O
the	B-O
score	I-O
of	I-O
symptoms	I-O
in	I-O
traditional	I-O
Chinese	I-O
medicine	I-O
(	I-O
TCM	I-O
)	I-O
were	O
observed	O
in	O
the	O
two	O
groups	O
and	O
the	O
clinical	O
therapeutic	O
effect	O
was	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
coronavirus	O
disease	O
2019	O
:	O
a	O
placebo	O
-	O
controlled	O
double	O
blind	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
multicentre	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
evaluating	O
hydroxychloroquine	B-I
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	I-P
at	I-P
least	I-P
one	I-P
of	I-P
the	I-P
following	I-P
risk	I-P
factors	I-P
for	I-P
worsening	I-P
:	I-P
need	I-P
for	I-P
supplemental	I-P
oxygen	I-P
,	I-P
age	I-P
?75	I-P
years	I-P
,	I-P
age	I-P
between	I-P
60	I-P
and	I-P
74	I-P
years	I-P
and	I-P
presence	I-P
of	I-P
at	I-P
least	I-P
one	I-P
co	I-P
-	I-P
morbidity	I-P
.	O

Severely	O
ill	O
patients	O
requiring	O
oxygen	O
therapy	O
>	O
3	O
L	O
/	O
min	O
or	O
intensive	O
care	O
were	O
excluded	O
.	O

Eligible	O
patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
800	B-I
mg	I-I
hydroxychloroquine	I-I
on	O
day	O
0	O
followed	O
by	O
400	O
mg	O
per	O
day	O
for	O
8	O
days	O
or	O
a	B-C
placebo	I-C
.	O

The	O
primary	O
end	O
point	O
was	O
a	B-O
composite	I-O
of	I-O
death	I-O
or	O
start	B-O
of	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
within	O
14	O
days	O
following	O
randomization	O
.	O

Secondary	O
end	O
points	O
included	O
mortality	B-O
and	O
clinical	B-O
evolution	I-O
at	O
days	O
14	O
and	O
28	O
,	O
and	O
viral	B-O
shedding	I-O
at	O
days	O
5	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Chloroquine	B-I
nasal	O
drops	O
in	O
asymptomatic	O
&	O
mild	O
COVID	O
-	O
19	O
:	O
An	O
exploratory	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
clinical	O
trial	O
was	O
done	O
with	O
a	O
sample	O
size	O
of	O
60	O
.	O

Reverse	B-P
transcription	I-P
-	I-P
polymerase	I-P
chain	I-P
reaction	I-P
(	I-P
RT	I-P
-	I-P
PCR	I-P
)	I-P
confirmed	I-P
asymptomatic	I-P
patients	I-P
or	I-P
those	I-P
with	I-P
mild	I-P
COVID	I-P
-	I-P
19	I-P
illness	I-P
[	I-P
National	I-P
Early	I-P
Warning	I-P
Score	I-P
(	I-P
NEWS	I-P
)	I-P
?4	I-P
]	I-P
were	O
included	O
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
manner	O
.	O

Control	O
arm	O
(	O
standard	B-C
supportive	I-C
treatment	I-C
,	O
n=30	O
)	O
was	O
compared	O
with	O
intervention	O
arm	O
(	O
n=30	O
)	O
of	O
standard	B-I
treatment	I-I
plus	O
CQN	B-I
eye	O
drops	O
(	O
0	O
.	O
03	O
%	O
)	O
repurposed	O
as	O
nasal	O
drops	O
administered	O
six	O
times	O
daily	O
(	O
0	O
.	O
5	O
ml	O
/	O
dose	O
)	O
for	O
10	O
days	O
.	O

Outcome	O
measures	O
were	O
adverse	B-O
events	I-O
and	O
adherence	B-O
;	O
clinical	B-O
progression	I-O
and	O
outcomes	O
were	O
measured	O
by	O
NEWS	B-O
;	O
sequential	B-O
RT	I-O
-	I-O
PCR	I-O
cycle	I-O
threshold	I-O
(	I-O
Ct	I-O
)	I-O
values	I-O
were	O
also	O
noted	O
on	O
days	O
0	O
,	O
3	O
,	O
7	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Telemanagement	O
of	O
Home	B-P
-	I-P
Isolated	I-P
COVID	I-P
-	I-P
19	I-P
Patients	I-P
Using	O
Oxygen	B-I
Therapy	I-I
With	O
Noninvasive	B-I
Positive	I-I
Pressure	I-I
Ventilation	I-I
and	O
Physical	B-I
Therapy	I-I
Techniques	I-I
:	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
In	O
this	O
single	O
-	O
blinded	O
randomized	O
clinical	O
trial	O
,	O
60	B-P
patients	I-P
with	I-P
stage	I-P
1	I-P
pneumonia	I-P
caused	I-P
by	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
were	O
treated	O
.	O

Group	O
A	O
(	O
n=30	O
)	O
received	O
oxygen	B-I
therapy	I-I
with	O
bilevel	B-I
positive	I-I
airway	I-I
pressure	I-I
(	I-I
BiPAP	I-I
)	I-I
ventilation	I-I
,	O
and	O
Group	O
B	O
(	O
n=30	O
)	O
received	O
osteopathic	B-I
manipulative	I-I
respiratory	I-I
and	O
physical	B-I
therapy	I-I
techniques	I-I
.	O

Arterial	B-O
blood	I-O
gases	I-O
of	I-O
PaO2	I-O
and	O
PaCO2	B-O
,	O
pH	B-O
,	O
vital	B-O
signs	I-O
(	O
ie	O
,	O
temperature	B-O
,	O
respiratory	B-O
rate	I-O
,	O
oxygen	B-O
saturation	I-O
,	O
heart	B-O
rate	I-O
,	O
and	O
blood	B-O
pressure	I-O
)	O
,	O
and	O
chest	B-O
computed	I-O
tomography	I-O
scans	I-O
were	O
used	O
for	O
follow	O
-	O
up	O
and	O
for	O
assessment	O
of	O
the	B-O
course	I-O
and	O
duration	B-O
of	I-O
recovery	I-O
.	O

-DOCSTART-	O

Title	O
:	O
What	O
about	O
tocilizumab	B-I
?	O
A	O
retrospective	O
study	O
from	O
a	O
NYC	O
Hospital	O
during	O
the	O
COVID	O
-	O
19	O
outbreak	O
.	O

METHODS	O
:	O
In	O
this	O
retrospective	O
analysis	O
of	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
admitted	I-P
between	I-P
March	I-P
2	I-P
and	I-P
April	I-P
14	I-P
,	I-P
2020	I-P
to	I-P
a	I-P
large	I-P
academic	I-P
medical	I-P
center	I-P
in	I-P
New	I-P
York	I-P
City	I-P
,	O
we	O
describe	O
outcomes	O
associated	O
with	O
tocilizumab	B-I
400	O
mg	O
(	O
without	B-I
methylprednisolone	I-I
)	O
compared	O
to	O
a	B-C
propensity	I-C
-	I-C
matched	I-C
control	O
.	O

The	O
primary	O
endpoints	O
were	O
change	O
in	O
a	B-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
of	I-O
oxygenation	I-O
and	O
ventilator	B-O
free	I-O
survival	I-O
,	O
both	O
at	O
days	O
14	O
and	O
28	O
.	O

Secondary	O
endpoints	O
include	O
incidence	B-O
of	I-O
bacterial	I-O
superinfections	I-O
and	O
gastrointestinal	B-O
perforation	I-O
.	O

Primary	O
outcomes	O
were	O
evaluated	O
using	O
t	O
-	O
test	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
two	O
-	O
arm	O
,	O
randomized	O
,	O
controlled	O
,	O
multi	O
-	O
centric	O
,	O
open	O
-	O
label	O
phase	O
-	O
2	O
study	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
Itolizumab	B-I
in	O
moderate	B-P
to	I-P
severe	I-P
ARDS	I-P
patients	I-P
due	I-P
to	I-P
COVID	I-P
-	I-P
19	I-P

OBJECTTIVE	O
:	O
Efficacy	O
and	O
safety	O
of	O
Itolizumab	O
,	O
an	O
immunomodulatory	O
mAb	O
,	O
in	O
treating	O
moderate	O
-	O
to	O
-	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
cytokine	O
release	O
in	O
COVID	O
-	O
19	O
patients	O
was	O
evaluated	O
in	O
a	O
multi	O
-	O
centric	O
,	O
open	O
-	O
label	O
,	O
two	O
-	O
arm	O
,	O
controlled	O
,	O
randomized	O
,	O
phase	O
-	O
2	O
study	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
(	O
2	O
:	O
1	O
)	O
to	O
Arm	O
-	O
A	O
(	O
best	B-I
supportive	I-I
care	I-I
[	I-I
BSC	I-I
]	I-I
+	O
Itolizumab	B-I
)	O
and	O
Arm	O
-	O
B	O
(	O
BSC	B-C
)	O
.	O

Primary	O
outcome	O
of	O
interest	O
was	O
reduction	O
in	O
mortality	B-O
30	O
-	O
days	O
after	O
enrollment	O
.	O

-DOCSTART-	O

Title	O
:	O
Methylprednisolone	B-I
or	O
dexamethasone	B-C
,	O
which	O
one	O
is	O
superior	O
corticosteroid	O
in	O
the	O
treatment	O
of	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
a	O
triple	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
prospective	O
triple	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
,	O
we	O
enrolled	O
86	B-P
hospitalized	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
from	I-P
August	I-P
to	I-P
November	I-P
2020	I-P
,	I-P
in	I-P
Shiraz	I-P
,	I-P
Iran	I-P
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
into	O
two	O
groups	O
to	O
receive	O
either	O
methylprednisolone	B-I
(	O
2	O
mg	O
/	O
kg	O
/	O
day	O
;	O
intervention	O
group	O
)	O
or	O
dexamethasone	B-C
(	O
6	O
mg	O
/	O
day	O
;	O
control	O
group	O
)	O
.	O

Data	O
were	O
assessed	O
based	O
on	O
a	B-O
9	I-O
-	I-O
point	I-O
WHO	I-O
ordinal	I-O
scale	I-O
extending	O
from	O
uninfected	O
(	O
point	O
0	O
)	O
to	O
death	O
(	O
point	O
8	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
nasal	B-I
corticosteroid	I-I
in	O
the	O
treatment	O
of	O
anosmia	O
due	O
to	O
COVID	O
-	O
19	O
:	O
A	O
randomised	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
designed	O
as	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
.	O

In	O
total	O
,	O
276	B-P
PCR	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
who	I-P
were	I-P
presented	I-P
to	I-P
the	I-P
outpatient	I-P
clinic	I-P
with	I-P
anosmia	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
the	B-I
betamethasone	I-I
group	O
,	O
138	O
participants	O
received	O
nasal	B-I
drops	I-I
of	I-I
betamethasone	I-I
3	O
times	O
daily	O
until	O
recovery	O
for	O
a	O
maximum	O
of	O
one	O
month	O
.	O

Similar	B-C
dose	I-C
of	I-C
9	I-C
%	I-C
NaCl	I-C
drops	O
was	O
administered	O
to	O
138	O
participants	O
in	O
the	B-C
placebo	I-C
group	O
.	O

